LISI

The Peugeot family was a shareholder in CID, LISI’s main shareholder, since 1977. In 1996, Peugeot Invest received a 25% interest in CID as a transfer from another Peugeot family group company.

In 2002, Peugeot Invest took a direct 5% stake in LISI.

In 2023, Peugeot Invest took part in the reorganisation of LISI’s shareholding structure, and converted its entire stake in CID into LISI shares and cash (€58 million received on the two parts of the transaction).

At 31 December 2023, Peugeot Invest (via its wholly owned subsidiary Peugeot Invest Assets) held 14% of LISI.

In January 2024, Peugeot Invest completed the sale of a 4% stake in LISI. Following this placement, Peugeot Invest remains the Group’s second-largest shareholder, with more than 10% of the share capital and two seats on the Board of Directors.

The value of the shareholding in the Net Asset Value and the consolidated financial statements is based on the share price at 31 December 2023.

Peugeot Invest Assets, represented by Guillaume Falguière, is a director of LISI and a member of the CSR Committee.

Marie-Hélène Peugeot-Roncoroni is a director of LISI and a member of the Appointments, Remuneration and Gouvernance and CSR Committees.

LISI AEROSPACE’s revenues (51% of Group sales) increased by 18.0%(1) to €839 million. In Q4 2023, the division recorded its eighth consecutive quarter of double-digit growth, on the back of a good recovery in the aerospace market. The European Fasteners business continued to rebound, rising 28.0%(1) over the year, benefiting from the ramp-up of single-aisle aircraft. The Structural Components business grew by 6.6%(1) over the year, but continued to be hampered by supply and recruitment difficulties.

In a global market that grew by 5.5%, LISI AUTOMOTIVE (37% of sales) grew by 10.4%(1) and achieved record sales of €610 million, boosted by a price effect and the growing importance of electromobility products. LISI MEDICAL (11% of sales) generated revenue of €182 million, up 23.0%(1). Growth is being driven in particular by new products for the miniinvasive robotic surgery market. LISI’s consolidated revenue amounted to €1,630 million, up 15.5%(1). The current operating income was €91 million, or 5.6% of revenue (down 0.7 points). The Group generated free cash flow of €22 million and net debt stood at €501 million (due to capital reorganisation).